Express News | Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

BreakingsAug 22 21:00

10-Q: Q2 2024 Earnings Report

SECAug 15 04:44 · Announcements

Express News | Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

BreakingsAug 14 21:00

Express News | Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

BreakingsJul 12 00:21

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success With Social Responsibility

GlobeNewswireJul 9 04:07

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

GlobeNewswireJun 27 00:46

Express News | Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for Tvgn 489 in Blood Advances

BreakingsJun 25 20:05

Tevogen Bio Set to Join Russell 3000 Index

Globe NewswireJun 13 03:45

Express News | Tevogen Bio Enters Into Agreement for up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

BreakingsJun 12 03:30

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

Yahoo FinanceJun 8 03:32

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

GlobeNewswireJun 7 06:14

10-Q: Quarterly report

SECMay 29 05:26 · Announcements

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

GlobeNewswireApr 26 21:23

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

Seeking AlphaMar 28 20:46

Semper Paratus Acquisition Corporation Regains Compliance With Certain Nasdaq Listing Requirement

GlobeNewswireSep 29, 2023 20:50

Tevogen Bio to Become Publicly Listed on NYSE via Business Combination With Semper Paratus Acquisition Corporation

GlobeNewswireJun 29, 2023 20:05